RhumbLine Advisers
OTLK icon

RhumbLine Advisers’s Outlook Therapeutics OTLK Stock Holding History

RhumbLine Advisers’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,170
Closed -$19.7K – 4228
2025
Q1 		$19.7K Sell
16,170
-171,880
-91% -$301K ﹤0.01% 3741
2024
Q4 		$355K Buy
188,050
+174,896
+1,330% +$720K ﹤0.01% 2887
2024
Q3 		$70.2K Buy
13,154
+2,563
+24% +$18.8K ﹤0.01% 3606
2024
Q2 		$78.2K Buy
10,591
+945
+10% +$7.59K ﹤0.01% 3588
2024
Q1 		$115K Sell
9,646
-46
-0.5% -$372 ﹤0.01% 3396
2023
Q4 		$76.4K Hold
9,692
– – ﹤0.01% 3530
2023
Q3 		$42.8K Sell
9,692
-24
-0.2% -$531 ﹤0.01% 3679
2023
Q2 		$338K Buy
9,716
+799
+9% +$21.8K ﹤0.01% 2938
2023
Q1 		$194K Buy
8,917
+1,642
+23% +$36.7K ﹤0.01% 2743
2022
Q4 		$157K Sell
7,275
-9
-0.1% -$196 ﹤0.01% 2842
2022
Q3 		$178K Buy
7,284
+510
+8% +$11.9K ﹤0.01% 2921
2022
Q2 		$138K Buy
6,774
+2,142
+46% +$61.6K ﹤0.01% 3003
2022
Q1 		$165K Buy
4,632
+2,235
+93% +$69.8K ﹤0.01% 2797
2021
Q4 		$65K Sell
2,397
-103
-4% -$3.67K ﹤0.01% 2968
2021
Q3 		$108K Buy
2,500
+201
+9% +$9.7K ﹤0.01% 2985
2021
Q2 		$115K Buy
+2,299
New +$107K ﹤0.01% 2962

Other funds holding OTLK

SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

RhumbLine Advisers's OTLK Position: Q2 2025 in Review

RhumbLine Advisers sold out of Outlook Therapeutics (OTLK) in Q2 2025, closing a stake of 16,170 shares — an estimated $19.7K sold.

RhumbLine Advisers first reported a position in OTLK in Q2 2021 and held it in 16 quarters. The position peaked at $355K in Q4 2024. 66 funds tracked by Wall St. Rank hold OTLK as of Q2 2025.

  • RhumbLine Advisers reported no remaining Outlook Therapeutics position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 16,170 Outlook Therapeutics shares in Q2 2025, an estimated $19.7K.
  • RhumbLine Advisers first reported a position in Outlook Therapeutics in Q2 2021 and held it in 16 quarters.
  • RhumbLine Advisers's Outlook Therapeutics position peaked at $355K in Q4 2024.
  • 66 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.